18 research outputs found
Thiazolyl N-Benzyl-Substituted Acetamide Derivatives: Synthesis, Src Kinase Inhibitory and Anticancer Activities
KX2-391 (KX-01/Kinex Pharmaceuticals), N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide, is a highly selective Src substrate binding site inhibitor. To understand better the role of pyridine ring and N-benzylsubstitution in KX2-391 and establish the structure-activity relationship, a number of N-benzyl substituted (2-morpholinoethoxy)phenyl)thiazol-4-yl)acetamide derivatives containing thiazole instead of pyridine were synthesized and evaluated for Src kinase inhibitory activities. The unsubstituted N-benzyl derivative (8a) showed the inhibition of c-Src kinase with GI50 values of 1.34 μM and 2.30 M in NIH3T3/c-Src527F and SYF/c-Src527F cells, respectively. All the synthesized compounds were evaluated for inhibition of cell proliferation of human colon carcinoma (HT-29), breast carcinoma (BT-20), and leukemia (CCRF-CEM) cells. 4-Fluorobenzylthiazolyl derivative 8b exhibited 64-71% inhibition in the cell proliferation of BT-20 and CCR5 cells at concentration of 50 μM
Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)
The discovery of potent, peptide
site directed, tyrosine kinase
inhibitors has remained an elusive goal. Herein we describe the discovery
of two such clinical candidates that inhibit the tyrosine kinase Src.
Compound <b>1</b> is a phase 3 clinical trial candidate that
is likely to provide a first in class topical treatment for actinic
keratosis (AK) with good efficacy and dramatically less toxicity compared
to existing standard therapy. Compound <b>2</b> is a phase 1
clinical trial candidate that is likely to provide a first in class
treatment of malignant glioblastoma and induces 30% long-term complete
tumor remission in animal models. The discovery strategy for these
compounds iteratively utilized molecular modeling, along with the
synthesis and testing of increasingly elaborated proof of concept
compounds, until the final clinical candidates were arrived at. This
was followed with mechanism of action (MOA) studies that revealed
tubulin polymerization inhibition as the second MOA
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)
The discovery of potent, peptide
site directed, tyrosine kinase
inhibitors has remained an elusive goal. Herein we describe the discovery
of two such clinical candidates that inhibit the tyrosine kinase Src.
Compound <b>1</b> is a phase 3 clinical trial candidate that
is likely to provide a first in class topical treatment for actinic
keratosis (AK) with good efficacy and dramatically less toxicity compared
to existing standard therapy. Compound <b>2</b> is a phase 1
clinical trial candidate that is likely to provide a first in class
treatment of malignant glioblastoma and induces 30% long-term complete
tumor remission in animal models. The discovery strategy for these
compounds iteratively utilized molecular modeling, along with the
synthesis and testing of increasingly elaborated proof of concept
compounds, until the final clinical candidates were arrived at. This
was followed with mechanism of action (MOA) studies that revealed
tubulin polymerization inhibition as the second MOA
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)
The discovery of potent, peptide
site directed, tyrosine kinase
inhibitors has remained an elusive goal. Herein we describe the discovery
of two such clinical candidates that inhibit the tyrosine kinase Src.
Compound <b>1</b> is a phase 3 clinical trial candidate that
is likely to provide a first in class topical treatment for actinic
keratosis (AK) with good efficacy and dramatically less toxicity compared
to existing standard therapy. Compound <b>2</b> is a phase 1
clinical trial candidate that is likely to provide a first in class
treatment of malignant glioblastoma and induces 30% long-term complete
tumor remission in animal models. The discovery strategy for these
compounds iteratively utilized molecular modeling, along with the
synthesis and testing of increasingly elaborated proof of concept
compounds, until the final clinical candidates were arrived at. This
was followed with mechanism of action (MOA) studies that revealed
tubulin polymerization inhibition as the second MOA